Zilovertamab Vedotin for Diffuse Large B-Cell Lymphoma

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting Phase 3 Interventional Study
Diffuse Large B-Cell Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,046 (estimated)
Sponsor
Merck Sharp & Dohme LLC · Industry
Who this trial is looking for

This trial is looking for patients with a specific type of lymphoma who have not received treatment before. Participants will receive a new treatment combined with standard chemotherapy to see if it helps them live longer without cancer progression.

Are You a Good Fit for This Trial?
Rules you out Heart diseaseActive autoimmune disease

You may be able to join if

  • I have been diagnosed with diffuse large B-cell lymphoma.
  • I have not received any prior treatment for my lymphoma.
  • I have PET positive disease.
  • My performance status is between 0 and 2.
  • My heart function is at least 45%.
  • I am controlled for HIV with medication.
  • I am HBsAg positive but have undetectable HBV viral load.
  • I had hepatitis C in the past but my viral load is undetectable.

You may not be able to join if

  • I have had my lymphoma change from a less aggressive type.
  • I have been diagnosed with primary mediastinal B-cell lymphoma.
  • I have stage I diffuse large B-cell lymphoma.
  • I have had a stroke or heart attack in the past 6 months.
  • I have significant heart disease.
  • I have ongoing serious nerve damage.
  • I have had a transplant.
  • I have an active autoimmune disease that needed treatment in the past 2 years.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues * Has positron emission tomography (PET) positive disease at scre…
Contacts

Toll Free Number

1-888-577-8839

Trialsites@msd.com

CONTACT